2 Stocks to Buy While Their Prices Are Down

NYSE: JNJ | Johnson & Johnson News, Ratings, and Charts

JNJ – Amid persistent market uncertainties due to rising inflation and a potential recession, we believe fundamentally sound, beaten-down stocks Johnson & Johnson (JNJ) and Costco Wholesale (COST) could gain solid momentum in the near term and could be wise investments now. Read on…

The stock market experienced wild swings in the first half of 2022, as evidenced by the CBOE Volatility Index’s (VIX) 28.4% year-to-date gains. Furthermore, the stock market is expected to remain under immense pressure due to sky-high inflation, consecutive interest rate hikes, and recessionary pressures.

In the current environment, investors prefer companies with solid profit margins and cash flows, as well as promising growth prospects. Such financially strong companies may be able to hedge against market uncertainties. The decline in such stocks due to the broader market sell-off has created an excellent opportunity to acquire these fundamentally sound stocks at bargain prices.

Given this backdrop, we believe quality stocks Johnson & Johnson (JNJ) and Costco Wholesale Corporation (COST), which have declined in price lately, could be solid additions to your portfolio.

Johnson & Johnson (JNJ)

JNJ is involved in researching, developing, manufacturing, and selling various healthcare products. The company operates in three segments: Consumer Health; Pharmaceuticals; and Medical Devices.

In June, J&J announced the opening of the new J&J Satellite Center for Global Health Discovery at Singapore’s Duke-NUS Medical School, founded by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse.

The Satellite Center at Duke-NUS, the first of the J&J Centers for Global Health Discovery in the Asia-Pacific region, aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by bringing together the talent and expertise of the world’s largest healthcare company with that of a leading academic institution.

JNJ’s reported sales increased 3% from the year-ago value to $24.02 billion for the second quarter ended June 30, 2022. The company’s adjusted net earnings surged 4.3% from the prior-year quarter to $6.91 billion, while its adjusted EPS increased 4.4% year-over-year to $2.59.

Analysts expect the EPS to increase 2.8% year-over-year to $10.07 in fiscal 2022. The consensus revenue estimate of $95.12 billion in fiscal 2022 represents a 1.4% increase from the same period last year. While the stock has gained 4.5% over the past nine months, it has plunged 4.5% over the past year to close its last trading session at $170.20.

JNJ’s POWR Ratings reflect this promising outlook. The company has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

JNJ also has an A grade for Stability and a B for Quality and Value. Within the F-rated Medical – Pharmaceuticals industry, it is ranked #6 of 174 stocks. Click here to see additional POWR Ratings for Sentiment, Momentum, and Growth for JNJ.

Costco Wholesale Corporation (COST)

COST and its subsidiaries operate membership warehouses in the United States, Puerto Rico, Canada, the United Kingdom, Mexico, Japan, Korea, Australia, Spain, France, Iceland, China, and Taiwan. It provides branded and private-label products in a large range of merchandise categories.

For the third quarter ended May 08, 2022, COST’s total revenue increased 16.2% from the year-ago value to $52.59 billion. Its operating income grew 7.7% year-over-year to $1.79 billion. The company’s net income surged 10.9% from the prior-year quarter to $1.35 billion, while its EPS rose 10.5% year-over-year to $3.04.

COST’s EPS is expected to grow at the rate of 13.7% per annum over the next five years. The consensus revenue estimate of $226.24 billion in fiscal 2022 represents a 15.5% increase from the same period last year. While the stock has gained 23.3% over the past year, it is down 5.4% year-to-date to close its last trading session at $541.90.

It is no surprise that COST has an overall B rating, which equates to Buy in our POWR Ratings system. The stock also has a B grade for Growth and Sentiment. In the A–rated Grocery Big/Box Retailers industry, it is ranked #27.

Beyond the POWR Ratings grades I have just highlighted, you can view COST ratings for Momentum, Value, and Stability.


JNJ shares were trading at $170.33 per share on Tuesday afternoon, up $0.13 (+0.08%). Year-to-date, JNJ has gained 0.85%, versus a -12.84% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
JNJGet RatingGet RatingGet Rating
COSTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

2 Warren Buffett Stocks to Buy and Never Sell

Warren Buffett’s long-term value investing strategy serves as a guide for investors to ensure high returns. With the market volatility becoming more severe after the Fed’s recent interest rate hike, Buffett’s top holdings could be ideal investments for long-term investors. To that end, buying and holding Johnson & Johnson (JNJ) and United Parcel Service (UPS) could be wise. Continue reading…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

:  |  News, Ratings, and Charts

The Most Sought-After Tech Stock to Buy Right Now

Shares of Microsoft (MSFT) have shed more than 25% year-to-date, with the rising interest rates causing a massive tech sell-off. However, the current low price level allows long-term investors to take a position in the stock to benefit from its solid growth prospects. The company has guided double-digit growth for fiscal 2023. Moreover, MSFT has been increasingly paying dividends, which should help generate a steady income stream. Read more…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

Read More Stories

More Johnson & Johnson (JNJ) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All JNJ News